RWP
BTAI icon

RWA Wealth Partners’s BioXcel Therapeutics BTAI Stock Holding History

RWA Wealth Partners’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-9
Closed -$1K – 293
2018
Q2 		$1K Buy
+9
New +$1.37K ﹤0.01% 768

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RWA Wealth Partners's BTAI Position: Q3 2018 in Review

RWA Wealth Partners sold out of BioXcel Therapeutics (BTAI) in Q3 2018, closing a stake of 9 shares — an estimated $1K sold.

RWA Wealth Partners first reported a position in BTAI in Q2 2018 and held it in 1 quarter. The position peaked at $1K in Q2 2018. 19 funds tracked by Wall St. Rank hold BTAI as of Q3 2018.

  • RWA Wealth Partners reported no remaining BioXcel Therapeutics position as of Q3 2018 after selling out during the quarter.
  • RWA Wealth Partners sold 9 BioXcel Therapeutics shares in Q3 2018, an estimated $1K.
  • RWA Wealth Partners first reported a position in BioXcel Therapeutics in Q2 2018 and held it in 1 quarter.
  • RWA Wealth Partners's BioXcel Therapeutics position peaked at $1K in Q2 2018.
  • 19 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2018.

Based on RWA Wealth Partners's 13F filing for Q3 2018, filed 14 Nov 2018.